RAD — Radiopharm Theranostics Share News
0.000.00%
Last trade - 00:00- AU$70.88m
- AU$34.53m
- AU$3.63m
Brief: New Clinical Trial Data Highlights RAD 101 (18F-Pivalate) Successfully Detects Brain Metastases
Brief: Lantheus Increases To 12.16% Shareholding In Radiopharm With US$5M (A$8M) Placement
Australia's Radiopharm Theranostics jumps on securing premium placement from US co Lantheus
Brief: Radiopharm Theranostics Says Lantheus Increases Shareholding In Co
Development Partnership With Lantheus
Australia's Radiopharm Theranostics rises on partnership with Lantheus
Brief: Radiopharm Achieves Nasdaq Listing Of American Depositary Shares
Brief: Radiopharm Theranostics Achieves Nasdaq Listing Of American Depositary Shares
Brief: Radiopharm Theranostics Partners With Atomvie
Brief: Radiopharm Theranostics Launches American Depositary Receipt Program
Brief: Radiopharm Theranostics Increases Ownership In Radiopharm Ventures
Brief: Radiopharm Theranostics Receives $2 Mln Payment From Lantheus
Brief: Radiopharm Targets Nasdaq Listing By End Of 2024
Australia's Radiopharm Theranostics gains on FDA nod for imaging agent trial
Brief: Radiopharm Theranostics Receives FDA Ind Approval For Phase 2B Trial In Brain Metastases
Australia's Radiopharm Theranostics rises after first patient dosed in lung cancer trial
Brief: Radiopharm Theranostics Says End Of Agreements With Lind Partners
Brief: Radiopharm Theranostics Completes A$70 Million Placement
Australia's Radiopharm Theranostics hits near 2-month high on premium placement